Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Aug;29(4):293–302. doi: 10.1007/BF00199218

Synthesis of site-specific methotrexate-IgG conjugates

Comparison of stability and antitumor activity with active-ester-based conjugates

J Kralovec 1, M Singh 1, M Mammen 1, A H Blair 1, T Ghose 1,✉
PMCID: PMC11038340  PMID: 2787696

Abstract

With a view to increasing drug incorporation without loss of antibody activity, tritium-labeled methotrexate (MTX) was covalently linked to a polyclonal rabbit IgG antibody against bovine serum albumin and a monoclonal mouse IgG antibody against human renal cancer (Dal K20) by a site-specific method based on hydrazone bond formation between MTX hydrazide and the aldehyde groups generated by periodate oxidation of carbohydrate moieties in IgG (which are uncommon in the antigen-binding region). These conjugates were compared with the corresponding non-site-specific MTX-IgG conjugates produced by the N-hydroxysuccinimide active-ester method with regard to synthesis, stability, retention of antibody activity, inhibition of the target enzyme dihydrofolate reductase and antitumor effect. Incorporation levels achieved with the hydrazide method were no greater than with the active-ester method, typically 6–7 mol MTX/mol IgG. Approximately the same dihydrofolate-reductase-inhibitory capacity was observed for MTX bound by either method. Hydrazide conjugates lost bound drug more rapidly than active-ester conjugates on freezing and thawing, on incubation at 37° C and 51° C, and in the presence of serum or rat liver homogenates. Exposure to rat liver homogenates at 37° C, pH 4.6, for 24 h led to the loss of 50%–60% of the bound drug from hydrazide conjugates compared to 20%–30% from the active ester conjugates. Bio-Gel P-2 chromatography of low-molecular-mass fractions, obtained after exposure of each of the conjugates to liver homogenates, revealed the presence of a compound that had the same elution volume and R F on thin-layer chromatography as free MTX. Enzyme-linked immunosorbent assay showed loss of antibody activity of both types of conjugates at 51° C and on freezing and thawing. In a clonogenic assay, the active-ester conjugate of Dal K20 appeared to be equally effective or slightly better as a tumor inhibitor than the corresponding hydrazide conjugate. The hydrazide method may be useful in linking MTX to those monoclonal antibodies that tend to denature when subjected to the active-ester method of linkage.

Keywords: Hydrazide, Hydrazone, Dihydrofolate, Antibody Activity, Incorporation Level

Footnotes

Abbreviations used: aBSA, rabbit anti-(bovine serum albumin) IgG; EDCI, 3-ethyl-1-(3-dimethylaminopropyl)carbodiimide; ELISA, enzyme-linked immunosorbant assay; IC50, concentration giving 50% inhibition; MTX, methotrexate; MTXAE, N-hydroxy-succinimide-based active ester of MTX; MTXAE-IgG, MTX-IgG conjugate prepared by the active-ester method; MTXH, methotrexate hydrazide; MTXH-IgG, MTX-IgG conjugate prepared by the hydrazide method; PBS, 0.01 M sodium phosphate, pH 7.1, containing 0.145 M sodium chloride; TLC, thin-layer chromatography

References

  • 1.Baldwin RW, Embleton MJ, Garnett MO, Pimm MV. Conjugates of monoclonal antibody 791T/38 with methotrexate in cancer therapy. NCI Monogr. 1987;3:95. [PubMed] [Google Scholar]
  • 2.Bayer EA, Wilchek M. The use of avidin-biotin complex as a tool in molecular biology. Methods Biochem Anal. 1980;26:1. doi: 10.1002/9780470110461.ch1. [DOI] [PubMed] [Google Scholar]
  • 3.Belinska M, Nimec Z, Galivan J. Characteristics of methotrexate polyglutamate formation in cultured hepatic cells. Arch Biochem Biophys. 1982;216:466. doi: 10.1016/0003-9861(82)90235-1. [DOI] [PubMed] [Google Scholar]
  • 4.Blair AH, Ghose T. Linkage of cytotoxic agents to immunoglobulins. J Immunol Methods. 1983;59:28. doi: 10.1016/0022-1759(83)90024-8. [DOI] [PubMed] [Google Scholar]
  • 5.Bough CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun. 1973;52:27. doi: 10.1016/0006-291x(73)90949-2. [DOI] [PubMed] [Google Scholar]
  • 6.Chua MM, Fan ST, Karush F. Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. Biochim Biophys Acta. 1984;800:291. doi: 10.1016/0304-4165(84)90408-2. [DOI] [PubMed] [Google Scholar]
  • 7.Clemo GR, Smith JM (1928) The reduction of p-dimethylaminobenzaldehyde and the preparation of p-dimethylaminobenzyl alcohol. J Chem Soc 2423
  • 8.Deguchi T, Chu TM, Leong SS, Horoszewicz JS, Lee CL. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. Cancer Res. 1986;46:3751. [PubMed] [Google Scholar]
  • 9.Dopp D, Dopp H. Carbonsaure-hydrazide. In: Falbe J, editor. Methoden der Organischen Chemie. Stuttgart: Houben-Weyl, Georg Thieme; 1985. p. 1154. [Google Scholar]
  • 10.Embleton MJ, Garnett MC, Baldwin RW. Use of an antitumor monoclonal antibody for targeting MTX. Protides Biol Fluids. 1984;32:429. [Google Scholar]
  • 11.Embleton MJ, Nabib NA, Garnett MC, Wood C. Unsuitability of monoclonal antibodies to oncogene proteins for antitumor drug targeting. Int J Cancer. 1986;38:821. doi: 10.1002/ijc.2910380607. [DOI] [PubMed] [Google Scholar]
  • 12.Endo N, Kato Y, Takeda Y, Saito M, Umemoto N, Kishida K, Hara T. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Res. 1987;47:1076. [PubMed] [Google Scholar]
  • 13.Endo N, Takeda Y, Kishida K, Kato Y, Saito M, Umemoto N, Hara T. Target selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody. Cancer Immunol Immunother. 1987;25:1. doi: 10.1007/BF00199293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Fields R, Dixon HBF. A spectrophotometric method for the microdetermination of periodate. Biochem J. 1968;108:883. doi: 10.1042/bj1080883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fogh J, Trempe G. New human tumor cell lines. In: Fogh J, editor. Human tumor cells in vitro. New York: Plenum Press; 1975. p. 115. [Google Scholar]
  • 16.Fry DW, Yolowich JC, Goldman ID. Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem. 1982;257:1890. [PubMed] [Google Scholar]
  • 17.Galivan J. Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res. 1979;39:735. [PubMed] [Google Scholar]
  • 18.Garnett MC, Baldwin RW. An improved synthesis of a methotrexate-albumin 791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines. Cancer Res. 1986;46:2407. [PubMed] [Google Scholar]
  • 19.Garnett MC, Embleton MJ, Jacobs E, Baldwin RW. Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer. 1983;31:661. doi: 10.1002/ijc.2910310520. [DOI] [PubMed] [Google Scholar]
  • 20.Gewitz DA, White JC, Randolph JK, Goldman ID. Formation of methotrexate polyglutamates in rat hepatocytes. Cancer Res. 1979;39:2914. [PubMed] [Google Scholar]
  • 21.Ghose T, Blair AH, Kralovec J, Mammen M, Uadia P. Synthesis and testing of antibody-antifolate conjugates for drug targeting. In: Rodwell JD, editor. Antibody-mediated delivery systems. New York: Marcel Dekker; 1988. p. 81. [PubMed] [Google Scholar]
  • 22.Ghose T, Blair AH, Kulkarni PN. Preparation of antibody-linked cytotoxic agents. Methods Enzymol. 1983;93:280. doi: 10.1016/s0076-6879(83)93050-1. [DOI] [PubMed] [Google Scholar]
  • 23.Hurwitz E, Levy R, Maron R, Wilcheck M, Arnon R, Sela M. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities. Cancer Res. 1975;35:1175. [PubMed] [Google Scholar]
  • 24.Hurwitz E, Wilchek M, Pitha J. Soluble macromolecules as carriers for daunorubicin. J Appl Biochem. 1980;2:25. [Google Scholar]
  • 25.Ito Y, Yamasaki Y, Seno N, Matsumoto I. Preparation of high capacity adsorbents using new hydrazino-carriers and their use for low and high performance affinity chromatography of lectins. J Biochem. 1986;99:1267. doi: 10.1093/oxfordjournals.jbchem.a135590. [DOI] [PubMed] [Google Scholar]
  • 26.Jallal B, Salesse K, Garnier J. A high-capacity affinity gel for the purification of the testicular lutropin receptor. C R Acad Sci. 1986;303:73. [PubMed] [Google Scholar]
  • 27.Johnson DA, Laguzza BC. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res. 1987;47:3118. [PubMed] [Google Scholar]
  • 28.Kanellos J, Pietersz GA, McKenzie JFC. Studies of methotrexate-monoclonal-antibody conjugates for immunotherapy. J Natl Cancer Inst. 1985;75:319. [PubMed] [Google Scholar]
  • 29.Karpinski KF, Haywards S, Tryphonas K. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbant assay. J Immunol Methods. 1987;103:189. doi: 10.1016/0022-1759(87)90289-4. [DOI] [PubMed] [Google Scholar]
  • 30.Kornguth ML, Neidle A, Wealsch H. The stability and rearrangement of ε-N-glutamyl-lysines. Biochemistry. 1963;2:740. doi: 10.1021/bi00904a020. [DOI] [PubMed] [Google Scholar]
  • 31.Kulkarni PN, Blair AH, Ghose T. Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res. 1981;41:2700. [PubMed] [Google Scholar]
  • 32.Kulkarni PN, Blair AH, Ghose T, Mammen M. Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo. Cancer Immunol Immunother. 1985;16:127. doi: 10.1007/BF00199228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lathan B, Hoff DD, Elslager E. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. Cancer Treat Rep. 1984;68:733. [PubMed] [Google Scholar]
  • 34.Lopes AD, Radcliffe RD, Coughlin DJ, Lee LS, McKearn TJ, Rodwell JD. Site-selective methotrexate-antibody conjugates yield a superior therapeutic effect in tumor xenograft-bearing nude mice. In: Prozanski W, Seligmann M, editors. Clinical immunology. New York: Elsevier; 1987. p. 303. [Google Scholar]
  • 35.Lowry OH, Rosebrough NJ, Farr AL, Randall R. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:165. [PubMed] [Google Scholar]
  • 36.Luner SJ, Ghose T, Chatterjee S, Cruz HN, Belitsky P. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res. 1986;46:5816. [PubMed] [Google Scholar]
  • 37.Manabe Y, Tsubota T, Haruta Y, Kataoka K, Okazaki M, Haisa S, Nakamura K, Kimura I. Production of a monoclonal antibody-methotrexate conjugate utilizing dextran-T40 and its biological activity. J Lab Clin Med. 1984;104:445. [PubMed] [Google Scholar]
  • 38.Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965;2:235. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  • 39.McKearn TJ, Lopes AD, Radcliffe RD, Coughlin DJ, Hrubiec RT, Rodwell JD (1989) In vivo efficacy of site-specific antifolate monoclonal antibody conjugates. Antibody Immunoconjugates and Radiopharmaceuticals (in press)
  • 40.McKinney M, Parkinson A. A simple non-chromagraphic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods. 1987;96:271. doi: 10.1016/0022-1759(87)90324-3. [DOI] [PubMed] [Google Scholar]
  • 41.Murayama A, Shimada K, Yamamoto T. Modification of immunoglobulin G using specific reactivity of sugar moiety. Immunochemistry. 1978;15:523. doi: 10.1016/0161-5890(78)90003-2. [DOI] [PubMed] [Google Scholar]
  • 42.O'Shannessy DJ, Quarles RH. Specific conjugation of the oligosaccharide moieties of immunoglobulins. J Appl Biochem. 1985;7:347. [PubMed] [Google Scholar]
  • 43.O'Shannessy DJ, Hoffman WL. Site-directed immobilization of glycoproteins on hydrazide-containing solid supports. Biotech Appl Biochem. 1987;9:488. doi: 10.1111/j.1470-8744.1987.tb00492.x. [DOI] [PubMed] [Google Scholar]
  • 44.O'Shannessy DJ, Dobersen MJ, Quarles RH. A novel procedure for labelling immunoglobulins by conjugation to oligosaccharide moieties. Immunol Lett. 1984;8:273. doi: 10.1016/0165-2478(84)90008-7. [DOI] [PubMed] [Google Scholar]
  • 45.Peterson DL, Gleisner JM, Blakley RL. Bovine liver dihydrofolate reductase: Purification and properties of the enzyme. Biochemistry. 1975;14:5261. doi: 10.1021/bi00695a005. [DOI] [PubMed] [Google Scholar]
  • 46.Pimm MV, Clegg JA, Garnett MC, Baldwin RW. Biodistribution and tumor localization of a methotrexate monoclonal-antibody 791T/36 conjugate in nude mice with human tumor xenografts. Int J Cancer. 1988;41:886. doi: 10.1002/ijc.2910410620. [DOI] [PubMed] [Google Scholar]
  • 47.Piper JR, Montgomery JA. Synthesis of α- and γ-substituted amides, peptides and esters of methotrexate and their evaluation as inhibitors of folate metabolism. J Med Chem. 1982;25:182. doi: 10.1021/jm00344a018. [DOI] [PubMed] [Google Scholar]
  • 48.Poser RG, Sirotnak FM, Chello PL. Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells. Biochem Pharmacol. 1980;29:2701. doi: 10.1016/0006-2952(80)90093-3. [DOI] [PubMed] [Google Scholar]
  • 49.Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JWF, King HD, Powsner MJ, McKearn TJ. Site specific covalent modification of monoclonal antibodies. In vitro and in vivo evaluations. Proc Natl Acad Sci USA. 1986;83:2632. doi: 10.1073/pnas.83.8.2632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rosowsky A, Yu C-S, Uren J, Lazarus H, Wick M. Methotrexate analogues 13. Chemical and pharmacological studies on amide, hydrazide and hydroxamic acid derivatives. J Med Chem. 1981;24:559. doi: 10.1021/jm00137a016. [DOI] [PubMed] [Google Scholar]
  • 51.Scheidegger JJ. Une micro-methode de l'immunoelectrophorese. Int Arch Allergy Appl Immunol. 1955;7:103. [PubMed] [Google Scholar]
  • 52.Shen W-C, Ryser HJ-P. Selective killing of Fc receptor-bearing tumor cells through endocytosis of a drug-carrying immune complex. Proc Natl Acad Sci USA. 1984;81:1445. doi: 10.1073/pnas.81.5.1445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Shih LB, Sharkey RM, Primus FJ, Goldenberg DM. Site specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. Int J Cancer. 1988;41:832. doi: 10.1002/ijc.2910410610. [DOI] [PubMed] [Google Scholar]
  • 54.Singh M, Kralovec J, Mezei M, Ghose T (1989) Inhibition of human renal cancer by methotrexate linked to a monoclonal antibody. J Urol (in press) [DOI] [PubMed]
  • 55.Sirotnak FM, Chello PL, DeGraw JI, Piper JR, Montgomery JR. In: Molecular action and targets for chemotherapeutic agents. Sartorelli AC, editor. New York: Academic Press; 1981. p. 349. [Google Scholar]
  • 56.Uadia PO, Blair AH, Ghose T. Hydrolysis of methotrexate-immunoglublin conjugates by liver homogenates and characterization of catabolites. Cancer Chemother Pharmacol. 1988;22:175. doi: 10.1007/BF00257318. [DOI] [PubMed] [Google Scholar]
  • 57.Weber K, Osborn M. The reliability of molecular weight determination by dodecyl sulphate-polyacrylamide gel electrophoresis. J Biol Chem. 1969;244:4406. [PubMed] [Google Scholar]
  • 58.Wilchek M, Bayer EA. Labeling glycoconjugates with hydrazide reagents. Methods Enzymol. 1987;138:429. doi: 10.1016/0076-6879(87)38037-1. [DOI] [PubMed] [Google Scholar]
  • 59.Wilchek M, Bayer EA. Labeling glycoconjugates with hydrazide reagents. Methods Enzymol. 1987;138:437. doi: 10.1016/0076-6879(87)38037-1. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES